Eli Lilly said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

A study by researchers at the Federal University of São Carlos (UFSCar) in Brazil, in partnership with University College ...

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...

Eli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too ...

The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.

Visceral obesity is associated with increased left ventricular mass and reduced ventricular volumes — suggesting concentric ...

Soybean oil, used for cooking in more than half of American households, is linked to a higher risk of obesity in a new study.

Soybean oil is regarded as beneficial to health, but this study suggests that you can have too much of a good thing and ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...